汤臣倍健(300146) - 2025 Q3 - 季度财报
By-healthBy-health(SZ:300146)2025-10-29 07:55

Financial Performance - The company's revenue for Q3 2025 reached ¥1,383,054,642.19, representing a 23.45% increase compared to the same period last year[4] - Net profit attributable to shareholders was ¥170,793,477.84, a significant increase of 861.91% year-on-year[4] - The net profit after deducting non-recurring gains and losses was ¥133,489,600.03, up 652.64% from the previous year[4] - For the period of January to September 2025, the company achieved operating revenue of RMB 4.915 billion, a decrease of 14.27% compared to the same period last year[21] - The net profit attributable to shareholders for the same period was RMB 907 million, an increase of 4.45% year-on-year[21] - The main brand "汤臣倍健" generated revenue of RMB 2.676 billion, down 16.22% year-on-year, while "健力多" revenue was RMB 574 million, down 17.76%[21] - The overseas brand LSG reported revenue of RMB 720 million, an increase of 13.64% year-on-year, with an Australian dollar revenue of AUD 157 million, up 17.36%[21] - The company reported total operating revenue of CNY 4,915,367,069.98 for the first nine months of 2025, a decrease of 14.3% compared to CNY 5,733,545,680.89 in the same period last year[29] - The net profit attributable to the parent company was CNY 907,306,713.44, representing an increase of 4.5% from CNY 868,614,585.23 in the previous year[30] Cash Flow and Investments - The company's cash flow from operating activities for the year-to-date was ¥921,241,875.10, an increase of 170.13%[4] - Cash flow from operating activities for the period was RMB 921 million, a significant increase of 170.13% compared to RMB 341 million in the previous period[16] - The net cash flow from investing activities improved to -RMB 5.79 million, a reduction of 86.23% from -RMB 42 million in the previous period[16] - Total cash inflow from financing activities was RMB 1.095 billion, an increase of 100.88% compared to RMB 545 million in the previous period[16] - Operating cash inflow totaled ¥4,854,131,782.80, a decrease of 8.2% from ¥5,286,441,798.25 in the previous period[32] - Net cash flow from operating activities increased significantly to ¥921,241,875.10, compared to ¥341,030,743.31 in the prior period, marking a growth of 170.5%[34] - Cash inflow from financing activities was ¥1,094,994,555.47, up from ¥545,098,899.99, indicating a growth of 100.8%[34] - The company repaid debts totaling ¥1,564,776,824.55 during the financing activities, with cash outflow for dividends and interest payments at ¥605,820,466.36[34] - The net increase in cash and cash equivalents was -¥271,814,282.04, compared to -¥942,848,920.13 in the previous period, showing an improvement[34] - The ending balance of cash and cash equivalents stood at ¥2,320,090,290.78, slightly down from ¥2,380,868,570.36[34] Assets and Liabilities - The total assets at the end of the reporting period were ¥14,002,293,222.35, a decrease of 1.94% from the end of the previous year[4] - The company's cash and cash equivalents decreased to CNY 2,320,090,290.78 from CNY 2,596,956,308.44 at the beginning of the period, a decline of 10.6%[26] - The total assets of the company as of September 30, 2025, were CNY 14,002,293,222.35, down from CNY 14,279,753,758.79 at the beginning of the year, a decrease of 1.9%[26] - The company’s total liabilities decreased to CNY 2,604,185,580.52 from CNY 3,182,576,755.69, a reduction of 18.1%[27] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 71,105, with the largest shareholder holding 42.01% of the shares[17] - The company repurchased a total of 9,168,400 shares, accounting for 0.539% of the total share capital, with a total payment of RMB 105.2 million[22] Research and Development - Research and development expenses decreased by 52.44% to ¥55,327,026.73, mainly due to refunds received from outsourced R&D[13] - The company’s R&D expenses for the first nine months were CNY 55,327,026.73, down 52.4% from CNY 116,330,568.98 in the previous year[30] Governance and Other Information - The company has restructured its governance by eliminating the supervisory board and transferring its responsibilities to the audit committee[23] - The company reported a basic earnings per share of CNY 0.53, compared to CNY 0.51 in the same period last year[30] - The company reported a significant increase in non-operating income, with government subsidies contributing to a 41.87% rise in other income to ¥39,581,509.49[13] - The company's financial report for Q3 2025 is unaudited[36]